EGFR and non-small cell lung carcinoma: Furthermore, 2 patients with EGFR-mutant NSCLC previously treated with EGFR tyrosine kinase inhibitors also had a second EGFR T790M mutation not previously identified in the FFPE tumor samples, which can plausibly explain why secondary resistance to EGFR targeted therapies occurred.